<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707326</url>
  </required_header>
  <id_info>
    <org_study_id>DUALING</org_study_id>
    <nct_id>NCT04707326</nct_id>
  </id_info>
  <brief_title>Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study</brief_title>
  <acronym>DUALING</acronym>
  <official_title>Defining the Potency of DTG/3TC for Suppressed HIV Patients in Real-life: the DUALING Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maasstad Hospital, Rotterdam</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MC Haaglanden, The Hague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Catharina Ziekenhuis Eindhoven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elisabeth Hospital, Tilburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital Arnhem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Admiraal de Ruyter Hospital, Goes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spaarne Gasthuis, Haarlem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MST, Enschede</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine real-life clinical efficacy of virally suppressed patienst&#xD;
      switching to DTG/3TC compared to DTG triple drug cART controls&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dolutegravir (DTG) based dual antiretroviral therapy constitutes a paradigm shift from triple&#xD;
      drug based therapy. Data outside clinical trials are scarce. This study evaluates the value&#xD;
      of DTG/3TC in real life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">November 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Efficacy OT</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of subjects with treatment failure in the DTG/3TC versus 3-drug DTG containing cART group up to 1 year of follow up in the OT population</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy ITT</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of subjects with treatment failure in the DTG/3TC versus 3-drug DTG containing cART group up to 1 year of follow up in the ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long term efficacy</measure>
    <time_frame>5 year</time_frame>
    <description>Proportion of subjects with treatment failure in the DTG/3TC versus 3-drug DTG containing cART group after 2 and 5 year of follow up in the OT and ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long term efficacy subgroups</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of subjects with treatment failure in the DTG/3TC versus 3-drug cART overall, and according to INSTI/PI/NNRTI (non-DTG) subgroups, after 1, 2 and 5 year of follow up in the OT and ITT population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event analysis</measure>
    <time_frame>5 years</time_frame>
    <description>Time to treatment failure in the DTG/3TC versus 3-drug DTG containing cART group and 3drug cART overall (including according to INSTI/PI/NNRTI (non-DTG) subgroups) according to the ITT and the OT population during 1, 2 and 5 years of follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma viral load</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of plasma viral load measurements above the limit of detection of the PCR but &lt;50 (between 20 and 50 c/mL), proportion of viral blips of HIVRNA &gt;50 once with plasma HIVRNA measured &lt;=50 c/mL before and after, proportion of plasma HIVRNA &gt;200 and &gt;1000c/mL on DTG/3TC versus 3-drug DTG containing cART group and 3drug cART overall and according to INSTI/PI/NNRTI (non-DTG) subgroups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug associated resistance</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of patients with emergent mutations associated with resistance to DTG, 3TC or the third antiviral agent in cases versus controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment failure predictors</measure>
    <time_frame>5 years</time_frame>
    <description>Predictor variables for treatment failure in the DTG/3TC, 3-drug (non) DTG containing cART group and 3drug cART overall at the 1, 2, and 5 years of follow up in the OT and ITT population according to 1) sex, 2) ethnicity (Caucasian, African, other), 3) CD4+Tcell nadir, 4) HIVRNA zenith, duration of suppressive cART (&lt;/&gt;1year and &lt;/&gt;5 year), 5) presence of mutations, 6) CD4/CD8 ratio nadir 7) documented history in ATHENA database of virological failure (without selection of M184VI or major DTG related RAMs) or inadherence.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Interim analysis</measure>
    <time_frame>3 and 4 years</time_frame>
    <description>Analysis of endpoints at 3 and 4 years of follow up</description>
  </other_outcome>
  <other_outcome>
    <measure>Side effects</measure>
    <time_frame>5 years</time_frame>
    <description>Proportion of subjects with switches due to side effects in the DTG/3TC versus 3-drug (non) DTG containing cART group and 3drug cART overall after 1, 2, 3, 4 and 5 years of follow up</description>
  </other_outcome>
  <other_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>5 years</time_frame>
    <description>Cost-effectiveness analysis of the switch from triple cART to DTG/3TC.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Hiv</condition>
  <arm_group>
    <arm_group_label>DTG/3TC</arm_group_label>
    <description>HIVRNA suppressed HIV patients who switched to DTG/3TC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple drug cART</arm_group_label>
    <description>Matched HIVRNA suppressed patients who remained on triple drug cART</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir / Lamivudine Pill</intervention_name>
    <description>HIVRNA suppressed patients without documented M184V mutation in HIV RT and who are hepatitis B immune or have no risk factors for acquiring hepatitis B</description>
    <arm_group_label>DTG/3TC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        To be eligible as case in the study, plasma HIVRNA must be &lt;50c/mL on triple drug cART&#xD;
        containing 2NRTI at switch to DTG/3TC and no key mutations associated with major 3TC (i.e.&#xD;
        M184V/I only) or DTG resistance of at least low level according to the Stanford HIV drug&#xD;
        resistance database should be present. Patients with no genotyping results available at&#xD;
        baseline will be eligible for inclusion in this study. Cases should not have documented&#xD;
        inadherence in the preceding 3 months or HepB coinfections. These data on adherence and&#xD;
        HepB is routinely collected at switching to DTG/3TC. Controls are matched on predefined&#xD;
        criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Plasma HIVRNA &lt;50c/mL on triple drug cART regimen including 2NRTI In care in a HIV&#xD;
        treatment center in the Netherlands Consented to ATHENA participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Documented mutations associated with 3TC or DTG resistance of at least low level Documented&#xD;
        inadherence by the treating physician or HepB coinfection (cases only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert-Jan Hassing, MD PhD</last_name>
      <phone>0880058888</phone>
      <email>rhassing@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heidi Ammerlaan, MD PhD</last_name>
      <phone>0402399111</phone>
      <email>heidi.ammerlaan@catharinaziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerrit Jan Kootstra, MD PhD</last_name>
      <phone>0534872000</phone>
      <email>g.kootstra@mst.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Ziekenhuis</name>
      <address>
        <city>Goes</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcel van den Berg, MD PhD</last_name>
      <phone>0881250000</phone>
      <email>m.vandenberge@adrz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Soetekouw, MD PhD</last_name>
      <phone>0232240000</phone>
      <email>soetekouw@spaarnegasthuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casper Rokx, MD PhD</last_name>
      <phone>0681336328</phone>
      <email>c.rokx@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bart Rijnders, MD PhD</last_name>
      <phone>0107040704</phone>
      <email>b.rijnders@erasmusmc.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Carlijn Jordans, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rosanne Verwijs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MC Haaglanden</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elianne Leyten, MD PhD</last_name>
      <phone>0889797900</phone>
      <email>e.leyten@haaglandenmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maasstad Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan den Hollander, MD PhD</last_name>
      <phone>0102911911</phone>
      <email>hollanderj@maasstadziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elisabeth Tweesteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjo van Kasteren, MD PhD</last_name>
      <phone>0132210000</phone>
      <email>m.vankasteren@etz.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Casper Rokx</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Other research groups can contact the PI with a research question to obtain IPD.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Up to 15 years</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

